The safety and efficacy of transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

The safety and efficacy of transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma) - Transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029101

Enrollment

Registered

2017-11-01

Start date

2018-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant bone and soft tissue tumor Sarcoma

Interventions

Transcutaneous carbon dioxide (CO2) application

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who have been histologically diagnosed as either malignant bone tumor or malignant soft tissue tumor. (2) Age 16 yo or more (3) More than 4 weeks since any prior therapy (4) PS 0-1 (5) The patient have consented to the study in the document

Exclusion criteria

Exclusion criteria: (1) Skin ulcer or pathological fracture in the treated area (2) Peripheral arterial disease or ischemic disease in the affected limb (3) Skin disease in the affected limb (4) Active infectious disease in the affected limb (5) Other medical or psychological unsuitable reasons

Design outcomes

Primary

Measure	Time frame
complication	—

Secondary

Measure	Time frame
antitumor effect local blood flow	—

Countries

Japan

Contacts

Public ContactNaomasa Fukase

Kobe University Graduate School of Medicine Department of Orthopaedic Surgery

nfukase@msn.com078-382-5985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026